JP2005502621A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502621A5
JP2005502621A5 JP2003510107A JP2003510107A JP2005502621A5 JP 2005502621 A5 JP2005502621 A5 JP 2005502621A5 JP 2003510107 A JP2003510107 A JP 2003510107A JP 2003510107 A JP2003510107 A JP 2003510107A JP 2005502621 A5 JP2005502621 A5 JP 2005502621A5
Authority
JP
Japan
Prior art keywords
hydrogen atom
hydroxy
alkyl
antibacterial agent
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003510107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502621A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2002/006670 external-priority patent/WO2003004098A1/en
Publication of JP2005502621A publication Critical patent/JP2005502621A/ja
Publication of JP2005502621A5 publication Critical patent/JP2005502621A5/ja
Pending legal-status Critical Current

Links

JP2003510107A 2001-07-06 2002-07-02 インターロイキン２阻害剤および抗菌剤を含む局所投与用組成物 Pending JP2005502621A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30314801P 2001-07-06 2001-07-06
PCT/JP2002/006670 WO2003004098A1 (en) 2001-07-06 2002-07-02 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent

Publications (2)

Publication Number Publication Date
JP2005502621A JP2005502621A (ja) 2005-01-27
JP2005502621A5 true JP2005502621A5 (enExample) 2006-01-05

Family

ID=23170731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003510107A Pending JP2005502621A (ja) 2001-07-06 2002-07-02 インターロイキン２阻害剤および抗菌剤を含む局所投与用組成物

Country Status (9)

Country Link
US (2) US7033604B2 (enExample)
EP (1) EP1406700A1 (enExample)
JP (1) JP2005502621A (enExample)
KR (1) KR20040019034A (enExample)
CN (1) CN1259049C (enExample)
AR (1) AR036127A1 (enExample)
CA (1) CA2452372A1 (enExample)
NZ (1) NZ530845A (enExample)
WO (1) WO2003004098A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406700A1 (en) 2001-07-06 2004-04-14 Sucampo AG Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
BR0313425A (pt) * 2002-08-09 2005-07-05 Sucampo Pharmaceuticals Inc Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
GB0307862D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP2007505932A (ja) * 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
KR101140039B1 (ko) * 2004-01-26 2012-05-02 (주)아모레퍼시픽 진세노사이드 ｆ1 또는 화합물 ｋ를 함유하는 피부외용제조성물
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2440185B1 (en) * 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20160051526A1 (en) * 2013-04-09 2016-02-25 Cresset Biomolecular Discovery Ltd The Local Treatment of Inflammatory Ophthalmic Disorders
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
EP3978512A1 (en) 2015-10-09 2022-04-06 Bioniz, LLC Modulating gamma-c-cytokine activity
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
KR102707650B1 (ko) 2017-04-07 2024-09-19 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
US4215199A (en) 1978-06-05 1980-07-29 Sandoz Ltd. Antibiotic production
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
ES2099112T3 (es) 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
ES2154262T3 (es) 1991-04-26 2001-04-01 Fujisawa Pharmaceutical Co Uso de compuestos macrolidos para enfermedades oculares.
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5489435A (en) * 1993-07-06 1996-02-06 Ratcliff; Perry A. Composition for treatment of abnormal conditions of the epithelium of bodily orifices
CA2194049A1 (en) * 1994-06-28 1996-01-11 Georgi Stankov Novel clinical uses of polyene macrolides
US6087358A (en) * 1995-06-26 2000-07-11 Pathogenesis Corporation Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof
US5885601A (en) * 1996-04-05 1999-03-23 Family Health International Use of macrolide antibiotics for nonsurgical female sterilization and endometrial ablation
US5929086A (en) * 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
US6248776B1 (en) * 1997-08-26 2001-06-19 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds
US5912255A (en) * 1998-02-27 1999-06-15 Bussell; Letantia Topical fluoroquinolone antibiotics combined with benzoyl peroxide
US6312715B1 (en) * 1998-05-01 2001-11-06 3M Innovative Properties Company Adhesive microsphere drug delivery composition
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
CZ20013769A3 (cs) 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
DE60006262T2 (de) * 1999-09-24 2004-05-13 Alcon, Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
AR033151A1 (es) 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
EP1406700A1 (en) 2001-07-06 2004-04-14 Sucampo AG Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
AU2002366028A1 (en) * 2001-11-21 2003-06-10 Sucampo Ag Use of fk506 and analogues for treating allergic diseases
JP2006503812A (ja) * 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−２阻害薬との組み合わせ
BR0313425A (pt) * 2002-08-09 2005-07-05 Sucampo Pharmaceuticals Inc Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial
AR042890A1 (es) * 2003-01-16 2005-07-06 Sucampo Pharmaceuticals Inc Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido

Similar Documents

Publication Publication Date Title
AR036127A1 (es) Composicion para administracion topica que comprende un inhibidor de interleucina 2 y un agente antimicrobiano y uso de estos ultimos para preparar dicha composicion
MY143564A (en) Quinoline derivatives and their use as mycobacterial inhibitors
NO20066041L (no) Anvendelse av substituerte kinolinderivater for behandlingen og legemiddelresistente mykobakterielle sykdommer
MX2010006182A (es) Derivados de isoxazolo-piridazina.
JP2008526999A5 (enExample)
CA2656716C (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
JP2011505347A5 (enExample)
JP2010539179A5 (enExample)
JP2010501478A5 (enExample)
CA2693180A1 (en) Fused bicyclic compound
CA2475619A1 (en) Piperidine derivatives
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
JP2018522927A5 (enExample)
JP2004529928A5 (enExample)
AR065297A1 (es) Formulaciones biodisponibles de compuestos heterociclicos
JP2005536531A5 (enExample)
JP2007527904A5 (enExample)
JP2005529935A5 (enExample)
ATE457306T1 (de) 4-aryl substituierte chinole und analoga als therapeutische wirkstoffe
WO2005023792A3 (en) Macrocyclic compounds useful as pharmaceuticals
CA2487252A1 (en) Esters in position 20 of camptothecins
AR043504A1 (es) Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
EA200800455A1 (ru) Антибактериальные производные хинолина
JPWO2021132311A5 (enExample)